CRP identifies homeostatic immune oscillations in cancer patients

A potential treatment targeting tool?

Brendon J. Coventry, Martin L. Ashdown, Michael A. Quinn, Svetomir Nenad Markovic, Steven L. Yatomi-Clarke, Andrew P. Robinson

Research output: Contribution to journalArticle

48 Citations (Scopus)

Abstract

The search for a suitable biomarker which indicates immune system responses in cancer patients has been long and arduous, but a widely known biomarker has emerged as a potential candidate for this purpose. C-Reactive Protein (CRP) is an acute-phase plasma protein that can be used as a marker for activation of the immune system. The short plasma half-life and relatively robust and reliable response to inflammation, make CRP an ideal candidate marker for inflammation. The high- sensitivity test for CRP, termed Low-Reactive Protein (LRP, L-CRP or hs-CRP), measures very low levels of CRP more accurately, and is even more reliable than standard CRP for this purpose. Usually, static sampling of CRP has been used for clinical studies and these can predict disease presence or recurrence, notably for a number of cancers. We have used frequent serial L-CRP measurements across three clinical laboratories in two countries and for different advanced cancers, and have demonstrated similar, repeatable observations of a cyclical variation in CRP levels in these patients. We hypothesise that these L-CRP oscillations are part of a homeostatic immune response to advanced malignancy and have some preliminary data linking the timing of therapy to treatment success. This article reviews CRP, shows some of our data and advances the reasoning for the hypothesis that explains the CRP cycles in terms of homeostatic immune regulatory cycles. This knowledge might also open the way for improved timing of treatment(s) for improved clinical efficacy.

Original languageEnglish (US)
Article number102
JournalJournal of Translational Medicine
Volume7
DOIs
StatePublished - Nov 30 2009

Fingerprint

C-Reactive Protein
Neoplasms
Therapeutics
Immune system
Biomarkers
Immune System
Clinical laboratories
Inflammation
Acute-Phase Proteins
Half-Life
Blood Proteins
Chemical activation
Sampling
Plasmas
Recurrence

ASJC Scopus subject areas

  • Biochemistry, Genetics and Molecular Biology(all)
  • Medicine(all)

Cite this

CRP identifies homeostatic immune oscillations in cancer patients : A potential treatment targeting tool? / Coventry, Brendon J.; Ashdown, Martin L.; Quinn, Michael A.; Markovic, Svetomir Nenad; Yatomi-Clarke, Steven L.; Robinson, Andrew P.

In: Journal of Translational Medicine, Vol. 7, 102, 30.11.2009.

Research output: Contribution to journalArticle

Coventry, Brendon J. ; Ashdown, Martin L. ; Quinn, Michael A. ; Markovic, Svetomir Nenad ; Yatomi-Clarke, Steven L. ; Robinson, Andrew P. / CRP identifies homeostatic immune oscillations in cancer patients : A potential treatment targeting tool?. In: Journal of Translational Medicine. 2009 ; Vol. 7.
@article{421b0504a6634be18ce3ddb8ec624a00,
title = "CRP identifies homeostatic immune oscillations in cancer patients: A potential treatment targeting tool?",
abstract = "The search for a suitable biomarker which indicates immune system responses in cancer patients has been long and arduous, but a widely known biomarker has emerged as a potential candidate for this purpose. C-Reactive Protein (CRP) is an acute-phase plasma protein that can be used as a marker for activation of the immune system. The short plasma half-life and relatively robust and reliable response to inflammation, make CRP an ideal candidate marker for inflammation. The high- sensitivity test for CRP, termed Low-Reactive Protein (LRP, L-CRP or hs-CRP), measures very low levels of CRP more accurately, and is even more reliable than standard CRP for this purpose. Usually, static sampling of CRP has been used for clinical studies and these can predict disease presence or recurrence, notably for a number of cancers. We have used frequent serial L-CRP measurements across three clinical laboratories in two countries and for different advanced cancers, and have demonstrated similar, repeatable observations of a cyclical variation in CRP levels in these patients. We hypothesise that these L-CRP oscillations are part of a homeostatic immune response to advanced malignancy and have some preliminary data linking the timing of therapy to treatment success. This article reviews CRP, shows some of our data and advances the reasoning for the hypothesis that explains the CRP cycles in terms of homeostatic immune regulatory cycles. This knowledge might also open the way for improved timing of treatment(s) for improved clinical efficacy.",
author = "Coventry, {Brendon J.} and Ashdown, {Martin L.} and Quinn, {Michael A.} and Markovic, {Svetomir Nenad} and Yatomi-Clarke, {Steven L.} and Robinson, {Andrew P.}",
year = "2009",
month = "11",
day = "30",
doi = "10.1186/1479-5876-7-102",
language = "English (US)",
volume = "7",
journal = "Journal of Translational Medicine",
issn = "1479-5876",
publisher = "BioMed Central",

}

TY - JOUR

T1 - CRP identifies homeostatic immune oscillations in cancer patients

T2 - A potential treatment targeting tool?

AU - Coventry, Brendon J.

AU - Ashdown, Martin L.

AU - Quinn, Michael A.

AU - Markovic, Svetomir Nenad

AU - Yatomi-Clarke, Steven L.

AU - Robinson, Andrew P.

PY - 2009/11/30

Y1 - 2009/11/30

N2 - The search for a suitable biomarker which indicates immune system responses in cancer patients has been long and arduous, but a widely known biomarker has emerged as a potential candidate for this purpose. C-Reactive Protein (CRP) is an acute-phase plasma protein that can be used as a marker for activation of the immune system. The short plasma half-life and relatively robust and reliable response to inflammation, make CRP an ideal candidate marker for inflammation. The high- sensitivity test for CRP, termed Low-Reactive Protein (LRP, L-CRP or hs-CRP), measures very low levels of CRP more accurately, and is even more reliable than standard CRP for this purpose. Usually, static sampling of CRP has been used for clinical studies and these can predict disease presence or recurrence, notably for a number of cancers. We have used frequent serial L-CRP measurements across three clinical laboratories in two countries and for different advanced cancers, and have demonstrated similar, repeatable observations of a cyclical variation in CRP levels in these patients. We hypothesise that these L-CRP oscillations are part of a homeostatic immune response to advanced malignancy and have some preliminary data linking the timing of therapy to treatment success. This article reviews CRP, shows some of our data and advances the reasoning for the hypothesis that explains the CRP cycles in terms of homeostatic immune regulatory cycles. This knowledge might also open the way for improved timing of treatment(s) for improved clinical efficacy.

AB - The search for a suitable biomarker which indicates immune system responses in cancer patients has been long and arduous, but a widely known biomarker has emerged as a potential candidate for this purpose. C-Reactive Protein (CRP) is an acute-phase plasma protein that can be used as a marker for activation of the immune system. The short plasma half-life and relatively robust and reliable response to inflammation, make CRP an ideal candidate marker for inflammation. The high- sensitivity test for CRP, termed Low-Reactive Protein (LRP, L-CRP or hs-CRP), measures very low levels of CRP more accurately, and is even more reliable than standard CRP for this purpose. Usually, static sampling of CRP has been used for clinical studies and these can predict disease presence or recurrence, notably for a number of cancers. We have used frequent serial L-CRP measurements across three clinical laboratories in two countries and for different advanced cancers, and have demonstrated similar, repeatable observations of a cyclical variation in CRP levels in these patients. We hypothesise that these L-CRP oscillations are part of a homeostatic immune response to advanced malignancy and have some preliminary data linking the timing of therapy to treatment success. This article reviews CRP, shows some of our data and advances the reasoning for the hypothesis that explains the CRP cycles in terms of homeostatic immune regulatory cycles. This knowledge might also open the way for improved timing of treatment(s) for improved clinical efficacy.

UR - http://www.scopus.com/inward/record.url?scp=72549117233&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=72549117233&partnerID=8YFLogxK

U2 - 10.1186/1479-5876-7-102

DO - 10.1186/1479-5876-7-102

M3 - Article

VL - 7

JO - Journal of Translational Medicine

JF - Journal of Translational Medicine

SN - 1479-5876

M1 - 102

ER -